New drug combo extends life for aggressive lung cancer patients

NCT ID NCT05683977

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 254 adults with extensive-stage small cell lung cancer who are receiving durvalumab (Imfinzi) along with standard chemotherapy. The goal is to see how long patients stay on treatment and how well it works in real-world settings. The approach uses the immune system to help fight the cancer, but ongoing treatment is needed to control the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SMALL CELL LUNG CARCINOMA

Contacts and locations

Show contact details

Locations

Research Site

Angers, 49933, France
Research Site

Argenteuil, 95107, France
Research Site

Avignon, 84000, France
Research Site

Avignon, 84918, France
Research Site

Bayonne, 64100, France
Research Site

Bordeaux, 33077, France
Research Site

Clermont-Ferrand, 63000, France
Research Site

Créteil, 94000, France
Research Site

Dijon, 21000, France
Research Site

Epagny Metz-Tessy, 74370, France
Research Site

Évreux, 27015, France
Research Site

Gleizé, 69400, France
Research Site

La Roche-sur-Yon, 85925, France
Research Site

La Rochelle, 17000, France
Research Site

Le Chesnay-Rocquencourt, 78150, France
Research Site

Limoges, 87000, France
Research Site

Marseille, 13008, France
Research Site

Nancy, 54100, France
Research Site

Nîmes, 30000, France
Research Site

Nîmes, 30900, France
Research Site

Osny, 95520, France
Research Site

Paris, 75005, France
Research Site

Pau, 64000, France
Research Site

Rennes, France
Research Site

Rouen, 76000, France
Research Site

Saint-Etienne, 42100, France
Research Site

Saint-Grégoire, 35760, France
Research Site

Saint-Quentin, 2321, France
Research Site

Toulon, 83000, France
Research Site

Toulouse, 31076, France
Research Site

Toulouse, 31400, France
Research Site

Valenciennes, 59300, France
Research Site

Vannes, 56017, France
Research Site

Villeurbanne, 69100, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.